Sp1279
AN INVESTIGATIONAL NEW MOA THAT CAN STABILIZE THE INFLAMMATORY RESPONSE IN ULCERATIVE COLITIS
Date
May 20, 2024
Presenter
Northwestern University Feinberg School of Medicine
Tracks
Related Products
Dr. Ellen Scherl — Jill Roberts Lecture: Artificial Intelligence in IBD
Artificial intelligence has emerged as an important tool to augment clinical care, assessment of endpoints and research…
PERSISTENCE OF SPLANCHNIC GENE SIGNATURE DEFINES A TUMOR-RESTRAINING FIBROBLAST SUBTYPE IN PANCREATIC CANCER
The pancreas is composed of the epithelial and mesenchymal cells. Interaction between the two lineages guides proper formation of the pancreas and modulates progression of pancreatic diseases such as cancer…
Epi II: Best of Observational Studies in IBD
SOCIETY: AGA This session highlights the best of the best observational studies in IBD for DDW 2024 and provides clinical relevant and novel insights across the age and clinical spectrum, including wound healing after C-section…
EFFICACY AND SAFETY OF OBEFAZIMOD IN UC PATIENTS AT WEEKS 48 AND 96 OF AN OPEN-LABEL MAINTENANCE STUDY AMONG CLINICAL RESPONDERS AT WEEK 8 OF THE PHASE 2B INDUCTION TRIAL
Obefazimod is an investigational, oral, once-daily, small molecule which enhances expression of microRNA-124 and is currently in phase 3 clinical trials for the treatment of patients with moderately to severely active ulcerative colitis (UC) [1]…
